Drug Trial Radar · NCT07894055
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Aug 12, 2026
Primary completion
Sep 25, 2026
Study completion Aug 25, 2027
Sponsor
- Lead sponsor
- Changchun BCHT Biotechnology Co.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
the immunogenicity and safety of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
Conditions
- Pertussis (Whooping Cough)
- Diphtheria
- Tetanus
Interventions
Tdap vaccineBiological
intramuscular injection only, and the preferred inoculation site is the deltoid muscle of the upper arm.
PlaceboBiological
intramuscular injection only, and the preferred inoculation site is the deltoid muscle of the upper arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion rates and geometric mean concentration of anti-DT antibodyTime frame: 30 days after injection
- Seroconversion rates and geometric mean concentration of anti-TT antibodyTime frame: 30 days after injection
- Seroconversion rates and geometric mean concentration of anti-PT antibodyTime frame: 30 days after injection
- Seroconversion rates and geometric mean concentration of anti-FHA antibodyTime frame: 30 days after injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ethics Review Committee of Zhejiang Provincial Center for Disease Control
Lishui, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.